Shilpa Medicare aims for US approval of chemo nausea drug
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The supplements are made using only vegetarian-sourced ingredients
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Subscribe To Our Newsletter & Stay Updated